title: Overnight food deprivation markedly attenuates hindbrain noradrenergic, glucagon-like peptide-1, and hypothalamic neural responses to exogenous cholecystokinin in male rats.
abstract: Systemic administration of sulfated cholecystokinin-8 (CCK) activates neurons within the hindbrain nucleus of the solitary tract (NTS) that project directly to the paraventricular nucleus of the hypothalamus (PVN), and these projections underlie the ability of exogenous CCK to activate the hypothalamic-pituitary-adrenal (HPA) stress axis. CCK inhibits food intake, increases NTS neuronal cFos expression, and activates the HPA axis in a dose-dependent manner. While the hypophagic effects of exogenous CCK are attenuated in food-deprived rats, CCK dose-response relationships for NTS and hypothalamic activation in fed and fasted rats are unknown. Within the NTS, noradrenergic A2 and glucagon-like peptide-1 (GLP-1) neurons express cFos after high doses of CCK, and both neuronal populations project directly to the medial parvocellular (mp)PVN. We hypothesized that increasing and correlated proportions of A2, GLP-1, and mpPVN neurons would express cFos in rats after increasing doses of CCK, and that food deprivation would attenuate both hindbrain and hypothalamic neural activation. To test these hypotheses, ad libitum-fed (ad lib) and overnight food-deprived (DEP) rats were anesthetized and perfused with fixative 90min after i.p. injection of 1.0ml saline vehicle containing CCK at doses of 0, 3, or 10μg/kg BW. Additional ad lib and DEP rats served as non-handled (NH) controls. Brain tissue sections were processed for dual immunocytochemical localization of cFos and dopamine-β-hydroxylase to identify A2 neurons, or cFos and GLP-1. Compared to negligible A2 cFos activation in NH control rats, i.p. vehicle and CCK dose-dependently increased A2 activation, and this was significantly attenuated by DEP. DEP also attenuated mpPVN cFos expression across all treatment groups, and A2 activation was strongly correlated with mpPVN activation in both ad lib and DEP rats. In ad lib rats, large and similar numbers of GLP-1 neurons expressed cFos across all i.p. treatment groups, regardless of CCK dose. Surprisingly, DEP nearly abolished baseline GLP-1 cFos expression in NH controls, and also in rats after i.p. injection of vehicle or CCK. We conclude that CCK-induced hypothalamic cFos activation is strongly associated with A2 activation, whereas the relationship between mpPVN and GLP-1 activation is less clear. Furthermore, activation of A2, GLP-1, and mpPVN neurons is significantly modulated by feeding status, suggesting a mechanism through which food intake and metabolic state might impact hypothalamic neuroendocrine responses to homeostatic challenge.
authors: Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, United States.
authors: James W
authors: JW
authors: Maniscalco
authors: Linda
authors: L
authors: Rinaman
mesh_terms: D000200:Action Potentials / Q000187:drug effects*; D000704:Analysis of Variance; D000818:Animals; D002766:Cholecystokinin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005508:Food Deprivation / Q000502:physiology*; D005786:Gene Expression Regulation / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism*; D016014:Linear Models; D008297:Male; D009434:Neural Pathways / Q000502:physiology; D009474:Neurons / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000166:cytology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017552:Solitary Nucleus / Q000378:metabolism*
chemical_list: D016760:Proto-Oncogene Proteins c-fos; D052216:Glucagon-Like Peptide 1; D002766:Cholecystokinin; D009638:Norepinephrine
keywords: CCK; Hypothalamic–pituitary–adrenal axis; Nucleus of the solitary tract; Paraventricular nucleus of the hypothalamus; cFos
references: Biochem Biophys Res Commun. 2001 Mar;281(5):1220-5
references: 11243865
references: Obes Res. 2002 Sep;10(9):932-8
references: 12226142
references: Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1544-9
references: 16384857
references: J Neurosci. 2007 Nov 28;27(48):13292-302
references: 18045923
references: Am J Physiol. 1986 May;250(5 Pt 2):R851-5
references: 3518495
references: Endocrinology. 2004 Aug;145(8):3652-7
references: 15105382
references: J Histochem Cytochem. 2008 Mar;56(3):285-93
references: 18040081
references: Am J Physiol Regul Integr Comp Physiol. 2005 Mar;288(3):R751-8
references: 15550621
references: Brain Res. 1999 Oct 30;846(1):1-11
references: 10536208
references: Am J Physiol. 1994 Jul;267(1 Pt 2):R303-8
references: 8048636
references: Science. 1981 Aug 28;213(4511):1036-7
references: 7268408
references: Physiol Behav. 1989 May;45(5):989-94
references: 2780885
references: J Neurosci. 2004 Nov 10;24(45):10240-7
references: 15537896
references: J Neuroendocrinol. 1991 Apr 1;3(2):139-44
references: 19215514
references: Regul Pept. 2009 Oct 9;157(1-3):84-91
references: 19540880
references: Peptides. 1992 Jan-Feb;13(1):203-5
references: 1620654
references: J Neurosci. 2003 Jul 16;23(15):6163-70
references: 12867498
references: Am J Physiol. 1999 May;276(5):R1545-9
references: 10233050
references: Physiol Behav. 2011 Nov 30;105(1):94-9
references: 21382391
references: J Neurosci. 1988 Aug;8(8):3018-24
references: 3411366
references: Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):504-10
references: 17563471
references: Am J Physiol Regul Integr Comp Physiol. 2011 Feb;300(2):R222-35
references: 20962208
references: Endocrinology. 2000 Dec;141(12):4442-8
references: 11108253
references: Endocrinology. 1992 Apr;130(4):1764-74
references: 1312423
references: Am J Physiol Cell Physiol. 2006 Feb;290(2):C427-32
references: 16192299
references: J Histochem Cytochem. 1974 Dec;22(12):1077-83
references: 4374474
references: J Comp Neurol. 1988 Aug 1;274(1):60-76
references: 2458397
references: Neuropharmacology. 1994 Jun;33(6):719-27
references: 7936109
references: J Comp Physiol Psychol. 1973 Sep;84(3):488-95
references: 4745816
references: J Comp Neurol. 1995 Sep 18;360(2):246-56
references: 8522645
references: Endocr Rev. 1989 Nov;10(4):437-58
references: 2558876
references: Am J Physiol. 1989 Feb;256(2 Pt 2):R463-8
references: 2537039
references: Am J Physiol. 1997 Apr;272(4 Pt 2):R1245-51
references: 9140026
references: J Neuroendocrinol. 1991 Apr 1;3(2):205-13
references: 19215523
references: J Chem Neuroanat. 2008 Dec;36(3-4):144-9
references: 18773953
references: Am J Physiol. 1988 Jul;255(1 Pt 2):R14-20
references: 3394837
references: J Neurosci. 2003 Nov 5;23(31):10084-92
references: 14602823
references: Physiol Behav. 2006 Nov 30;89(4):477-85
references: 16872644
references: Endocrinology. 1987 Sep;121(3):924-30
references: 3497798
references: Am J Physiol. 1993 Oct;265(4 Pt 2):R872-6
references: 8238459
references: Brain Res. 1997 Oct 3;770(1-2):277-88
references: 9372230
references: Brain Res Dev Brain Res. 1994 Jan 14;77(1):140-5
references: 8131259
references: Proc Soc Exp Biol Med. 2000 Jul;224(3):152-8
references: 10865230
references: Neurosci Lett. 1993 Jan 4;149(1):91-4
references: 7682304
references: Brain Res. 1993 Sep 24;623(1):161-6
references: 8221086
references: Am J Physiol. 1991 Nov;261(5 Pt 2):R1141-6
references: 1951762
references: Am J Physiol. 1985 Nov;249(5 Pt 2):R638-41
references: 4061684
references: Endocrinology. 1997 Oct;138(10):4445-55
references: 9322962
references: Histochemistry. 1986;85(2):95-106
references: 2875047
references: Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1495-503
references: 17670858
references: Am J Physiol. 1999 Aug;277(2):R582-90
references: 10444567
references: Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R845-54
references: 19176891
references: Neuroscience. 2008 Oct 28;156(4):1093-102
references: 18773942
references: Front Neuroendocrinol. 2007 Apr;28(1):50-60
references: 17391741
references: Neuroendocrinology. 1985 Jul;41(1):17-22
references: 3927181
references: Brain Res. 1990 Aug 27;526(1):95-102
references: 2078822
references: Endocrinology. 1999 Sep;140(9):4015-23
references: 10465271
references: Brain Res. 1985 Sep 2;342(1):187-90
references: 4041813
references: Brain Res. 2010 Sep 2;1350:18-34
references: 20353764
references: Exp Physiol. 1991 Jul;76(4):525-31
references: 1910760
references: Peptides. 1986 Jan-Feb;7(1):155-9
references: 3520509
references: Brain Res. 1998 Apr 27;791(1-2):157-66
references: 9593872
references: J Neurosci. 2002 Feb 1;22(3):959-69
references: 11826124
references: Endocrinology. 2003 Apr;144(4):1357-67
references: 12639919
references: Eur J Neurosci. 2001 Oct;14(7):1143-52
references: 11683906
references: J Comp Neurol. 2001 Apr 2;432(2):197-216
references: 11241386
references: Am J Clin Nutr. 1977 May;30(5):758-61
references: 404865
references: Neuroscience. 1997 Mar;77(1):257-70
references: 9044391
references: J Neurosci. 2004 Sep 15;24(37):8141-52
references: 15371515
references: Regul Pept. 2000 Aug 25;92(1-3):79-85
references: 11024569
references: Neuroscience. 2000;96(4):743-51
references: 10727792
references: Am J Physiol. 1988 Jun;254(6 Pt 2):R853-6
references: 3381910
references: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2359-64
references: 8637878
references: Brain Res. 2003 Sep 26;985(2):163-8
references: 12967720